Full Breakdown
Eli Lilly's Potential €15 Billion Acquisition of Abivax Sparks Market Surge
1/12/2026, 8:22:10 PM
Abivax Stock Soars on Acquisition Speculation
Abivax (EPA: ABVX), a French biotech firm, experienced a significant stock surge of approximately 30% in early trading on the Euronext exchange, following reports that U.S. pharmaceutical giant Eli Lilly is preparing a €15 billion ($17.5 billion) acquisition offer. This proposed buyout would nearly double Abivax's current market capitalization of €7.77 billion ($9.08 billion) and represents one of the largest pharmaceutical acquisitions in recent history. The stock climbed to an intraday peak of 130 euros, reflecting a remarkable 1,742% increase over the past year, largely driven by investor confidence in Abivax's lead drug candidate, obefazimod, for treating ulcerative colitis.
Eli Lilly's Strategic Interests
Eli Lilly's interest in acquiring Abivax aligns with its strategy to diversify its portfolio beyond its successful diabetes and obesity drugs. The company has recently completed a $1.2 billion acquisition of Ventyx Biosciences, indicating a strong commitment to expanding its capabilities in immunology and inflammatory diseases. Analysts have estimated Abivax's fair valuation between €12 billion and €20 billion, suggesting that the reported offer is within a reasonable range, although some investors speculate that Eli Lilly may enhance the terms based on upcoming trial results for obefazimod.
Background on Abivax and Obefazimod
Abivax's obefazimod has shown promising results in clinical trials, achieving a placebo-adjusted clinical remission rate of 19.3% in ulcerative colitis patients. The drug is currently undergoing multiple Phase 3 trials and is positioned as a potential first-in-class oral treatment for inflammatory bowel disease (IBD). The market for ulcerative colitis treatments is projected to grow significantly, reaching up to $15.5 billion by 2033, making Abivax's drug a valuable asset for Eli Lilly.
Official Statements & Responses
While Eli Lilly has not confirmed the acquisition talks, it is reportedly seeking guidance from the French Finance Ministry regarding potential foreign investment regulations that could impact the deal. Abivax's CEO, Marc de Garidel, refrained from commenting on the rumors but acknowledged the need for a partner to successfully bring obefazimod to international markets.
Criticism & Opposition
Despite the positive market response, there are concerns regarding the acquisition's regulatory hurdles. The French Ministry of the Economy has stated that it has not been contacted by Eli Lilly regarding the acquisition, which could complicate the deal's progression. Analysts have expressed caution, noting that while the speculation is credible, formal confirmations from either company are still pending.
Conflicting Reports & Gaps
The market's reaction to the acquisition rumors has been mixed, with some analysts raising target prices for Abivax shares significantly, while others emphasize the uncertainty surrounding the regulatory process. The French government's denial of contact with Eli Lilly adds another layer of complexity to the situation, highlighting the need for clarity on the acquisition's feasibility.
What's Next
As the market awaits further developments, analysts will closely monitor upcoming trial results for obefazimod, expected in Q2 2026, which could influence the acquisition terms and overall market sentiment regarding both companies.
